Cirino brings over 25 years of spine industry experience with numerous leadership roles in sales and marketing. Prior to joining SeaSpine, Cirino spent eight years at NuVasive Inc., where he served in roles of increasing seniority, most recently serving as vice president of market development for computer-assisted surgery. Prior to NuVasive, Cirino spent 10 years at Medtronic plc, where he held senior marketing, development and marketing services positions focused on spinal systems, biologics, and pain stimulation. Cirino has a bachelor of science degree in business administration from Duquesne University and a master's degree in business administration from the University of Notre Dame.
As senior vice president of Spinal Systems, Cirino will lead all aspects of the company’s spinal implants activities and initiatives. In this capacity, he will set direction for product innovation and development, marketing services, surgeon and sales education, and international strategy.
“Dennis’ deep experience building robust marketing programs, implementing international strategy, and driving surgeon education will serve us well as we leverage our recently launched and increasingly differentiated products, which are critical to accelerating our revenue growth,” said Keith Valentine, president and CEO of SeaSpine. “His strong relationships in the spine industry further strengthen our surgeon-centric approach to product innovation and mission to deliver cost effective solutions to improve the quality of patient lives.”
As an inducement to accepting employment with the company, on June 30, the Compensation Committee of the company’s Board of Directors approved a restricted stock unit award to Cirino with respect to 39,619 shares of SeaSpine common stock, as well as restricted stock unit awards to seven new, non-executive employees with respect to an aggregate of 6,660 shares of SeaSpine common stock. The awards are being granted under SeaSpine’s 2018 Employment Inducement Incentive Award Plan, which was adopted on June 29, and provides for the granting of equity awards to new employees of SeaSpine.
“SeaSpine’s focus on innovation and clinical value coupled with its increasing investment in medical education and training has positioned the company as the spine company of choice among both surgeons and distributors,” said Cirino. “I am thrilled to join this outstanding team and look forward to contributing to their powerful vision.”
SeaSpine designs, develops, and commercializes surgical solutions for treating spinal disorders. SeaSpine has a portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of a line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete procedural solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.